Gelteq
Gelteq is an Australian biotech that licenses a patented gel-based oral drug and nutrient delivery platform to pharmaceutical, nutraceutical, and animal health partners globally, addressing bioavailability, taste masking, and swallowing challenges through proprietary gelification technology developed with Monash University.
- Company typePublic
- Founded2016
- HeadquartersCaulfield, Australia
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Gelteq does
Gelteq is an Australian clinical-stage biotechnology company that has developed and patented a proprietary gel-based oral drug and nutrient delivery platform. Founded around 2016–2017 and headquartered at Monash Innovation Labs in Clayton, Victoria, the company's technology was co-developed with Monash University's Institute of Pharmaceutical Sciences (MIPS), ranked #1 globally for Pharmacy & Pharmacology in the 2024 QS World University Rankings. The core innovation is a gelification process that forms chemically and physically stable matrices capable of simultaneously integrating water-soluble and lipid-soluble compounds, addressing bioavailability and taste-masking challenges that affect over 40% of approved drugs. Preclinical and pharmacokinetic data report a 300% first-hour bioavailability improvement for oil-soluble compounds versus FDA-approved reference products and 38–45% improvement for water-soluble drugs such as antihistamines.
The company monetizes through a B2B licensing and partnership model. Gelteq licenses its proprietary gel formulations for white-label production by pharmaceutical, nutraceutical, and animal health partners; provides fee-for-service contract development and clinical support; and, through select distribution agreements, sells finished gel products directly. Named partners include Phynova and Reducose in pharmaceuticals, Healthy Extracts Inc. for US-based manufacturing and global distribution, Shenzhen Mana Health Management for exclusive China distribution of nutritional products (minimum ~USD 1.3M over three years), IDT Australia for cGMP manufacturing, and Kemin Industries for animal health validation. The company's commercial footprint spans Australia, the United States, and China, with active product candidates in veterinary antiparasitic clinical trials (FDA pathway), preclinical diabetes gels, and an antihistamine gel demonstrating pharmacokinetic gains.
Gelteq Limited is publicly traded on Nasdaq (GLTQ) and the ASX (GTQ), with a market capitalization of approximately $5.2M as of June 2026. The company is unprofitable, has 1–10 employees, and is currently funded in part by a $3.5M convertible debt facility (May 2026) to support clinical programs and commercial scale-up. It has received a Nasdaq minimum bid price deficiency notice with a compliance deadline of September 14, 2026, and its shares have declined approximately 71% over the prior year.
Gelteq firmographics
Firmographics- Name
- Gelteq
- Legal name
- Gelteq Limited
- Website
- https://gelteq.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Gelteq is an Australian biotech that licenses a patented gel-based oral drug and nutrient delivery platform to pharmaceutical, nutraceutical, and animal health partners globally, addressing bioavailability, taste masking, and swallowing challenges through proprietary gelification technology developed with Monash University.
- Ownership category
- akta.pro rank
Gelteq industry classification
Industry- Product category
- Drug Delivery Technology
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gelling Agents & Systems (Gelatin, Agar, Gellan, Konjac) (AFAJACAH)
- akta.pro secondary industries
- Gelatin & Collagen Hydrolysates (Animal-Based Gelling Agents) (AFAJABAD), Hydrocolloids, Thickeners & Gelling Agents (Pectin, Xanthan, Carrageenan, Gelatin) (CRADAOAD), Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM), Specialty & Condition-Specific Nutraceuticals (e.g., Liver, Eye, Endocrine) (HLAMALAO)
Keywords
Where Gelteq is headquartered
LocationHeadquarters
- HQ city
- Caulfield
- HQ country
- Australia
- HQ region
- Oceania
Offices4 records
Markets served
Gelteq business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Technology Licensing: Gelteq licenses its proprietary gel technology to pharmaceutical, nutraceutical, and animal health companies. Partners can white-label existing formulations or develop custom gel products using Gelteq's platform. The company retains full ownership of its intellectual property while enabling partners to manufacture and distribute gel-based products.
- Manufacturing & Distribution Partnership: Through partnerships like the Healthy Extracts MoU, Gelteq enables large-scale manufacturing and global distribution of gel products. Healthy Extracts serves as primary manufacturer and distributor while Gelteq provides formulations and technical transfer.
- Product Sales (Direct): Direct sales of gel-based nutritional products through distribution agreements. The three-year agreement with Shenzhen Mana Health Management Co. specifies minimum revenue of approximately USD 1.3 million for nutritional products in China.
- Contract Development: Fee-for-service formulation development and clinical trial support for pharmaceutical and nutraceutical companies seeking to leverage Gelteq's gel platform for their compounds.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Gelteq product offering
Product offeringCore offering
Gelteq develops, licenses, and white-labels a proprietary patented gel-based oral drug delivery platform that converts pharmaceutical, nutraceutical, and animal health compounds into a stable, ingestible gel matrix. The company provides formulation development, contract research, white-label gel formulations, and partnership-based commercialization across pharmaceutical, nutraceutical, veterinary, and sports nutrition verticals.
Product overview
Gelteq offers a proprietary gel-based oral drug delivery platform as its core technology, enabling the conversion of existing compounds into gel-based formats. The company operates across four main market segments: pharmaceuticals (partnered with Phynova and Reducose), nutraceuticals, pet/veterinary health, and sports performance. Key product candidates include an antiparasitic veterinary drug in clinical trials for FDA approval, diabetes gel products developed with Monash University MIPS, and an antihistamine product showing 38-45% bioavailability improvements. Gelteq provides both custom formulation services and white-label market-ready gel products, with recent expansion through manufacturing partnerships including IDT Australia and Healthy Extracts Inc.
Differentiator
Problem solved
Functional benefit
Products and services
- Gelteq Gel-Based Oral Drug Delivery Platform
- Pharmaceutical Gel Products
- Nutraceutical Gel Products
Quantifiable outcome
- 300% increase in bioavailability of oil-soluble compounds in the first hour compared to FDA-approved reference product
- +4 more outcomes
Companies that use Gelteq
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Gelteq technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Gelteq partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered major and core.
- Kemin IndustriesmajorSuccessful completion of veterinary palatability trials demonstrating strong canine acceptance across various flavour profiles including products with natural bitter compounds. Results confirmed Gelteq technology's ability to effectively mask bitter flavours while improving palatability, validating the platform for veterinary pharmaceutical applications and supporting partnership discussions with animal health organizations.
- Healthy Extracts Inc.coreStrategic manufacturing and commercial partnership for gel-based nutraceutical products. Healthy Extracts serves as primary manufacturer, commercial seller, and distribution partner using Gelteq's proprietary formulations and technical expertise. Enables large-scale US manufacturing and global distribution while Gelteq retains full IP ownership. Partnership includes plans to expand into China and positions gel-based formats as a growth frontier in functional nutrition.
- Shenzhen Mana Health Management Co. Ltd.majorThree-year sales agreement for distribution of nutritional products in China. Deal expected to generate minimum revenue of approximately USD 1.3 million and represents strategic expansion into China's growing wellness market.
- IDT AustraliacoreMoU for establishment of dedicated local manufacturing facility for gel-based pharmaceutical, nutraceutical, and animal health products. Leverages IDT's more than 50 years of pharmaceutical development and cGMP manufacturing expertise including FDA, TGA, and APVMA regulatory capabilities to support Gelteq's product scale-up for global markets.
- Monash University - Institute of Pharmaceutical Sciences (MIPS)coreFull-time R&D partnership with Monash University, ranked #1 globally in pharmaceutical science (2024 QS World University Rankings). MIPS formed as partnership between Monash University, Monash Institute of Pharmaceutical Science, and Victorian state government to create world-class biotechnology and medical research precinct. Global clients include GSK, Phillips, Roche, and Pfizer. MIPS serves as Gelteq's exclusive research and formulation development partner, with collaboration including development of diabetes-based gel products.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Gelteq competitors and assessment
Company assessmentDirect peers
- Catalent: Catalent is a global CDMO with proprietary softgel and oral drug delivery platforms serving pharma and consumer health. It is the most direct analog to Gelteq's gel-based oral delivery concept, with a comparable B2B licensing and formulation-development model.
- Evonik Industries: Evonik's Health Care division supplies specialty excipients and drug delivery technologies (including lipid-based and polymer systems such as EUDRAGIT) to pharmaceutical customers. Direct comparability to Gelteq's delivery-platform and excipient-licensing business model.
- Roquette: Roquette supplies pharmaceutical excipients including cyclodextrins and starches that address bioavailability challenges for poorly soluble APIs. Comparable in serving pharma formulation teams with solubilization technology, overlapping with Gelteq's core value proposition.
- Ashland: Ashland's pharmaceutical division provides controlled-release polymers and specialty excipients for oral solid dosage forms. Comparable to Gelteq as a specialty excipient/delivery platform supplier enabling partner drug reformulation.
- AptarGroup: AptarGroup is a global leader in drug delivery devices and dispensing systems for pharma, consumer health, and food/beverage. Comparable to Gelteq across target end-markets and B2B partnership model, though focused on device rather than formulation delivery.
- Gattefossé: Gattefossé specializes in lipid-based excipients and oral drug delivery systems for bioavailability enhancement. Directly comparable to Gelteq's dual water/lipid soluble delivery capability and pharma formulation partner model.
- Colorcon: Colorcon provides controlled-release coatings, excipients, and formulation services to pharma and nutraceutical customers. Comparable as a B2B specialty ingredient/delivery platform serving oral dosage reformulation.
- SPI Pharma: SPI Pharma develops specialty excipients and drug delivery platforms including taste-masking and fast-dissolve technologies for pharma and nutraceutical customers. Comparable to Gelteq's taste-masking, palatability, and oral bioavailability focus areas.
- Lubrizol Life Science: Lubrizol's Carbopol polymers are widely used in oral pharmaceutical formulations for controlled release and bioavailability enhancement. Comparable to Gelteq as a polymer-based drug delivery platform serving pharma formulation teams.
Broad incumbents
- Lonza Group: Lonza is a large global CDMO offering development, manufacturing, and delivery services across biologics, small molecules, and drug product. Comparable as a broader pharmaceutical services incumbent, though Lonza's scale and breadth materially exceed Gelteq's specialized gel platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Gelteq social profiles
Digital presenceGelteq financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gelteq leadership team
Management profileNumber of profiles
Profiles4 records
Gelteq funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gelteq M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gelteq
What does Gelteq do?
Gelteq develops, licenses, and white-labels a proprietary patented gel-based oral drug delivery platform that converts pharmaceutical, nutraceutical, and animal health compounds into a stable, ingestible gel matrix. The company provides formulation development, contract research, white-label gel formulations, and partnership-based commercialization across pharmaceutical, nutraceutical, veterinary, and sports nutrition verticals.
Is Gelteq a public or private company?
Gelteq is a public company. It is classified as public and is currently operating.
When was Gelteq founded?
Gelteq was founded in 2016. It employs 1 to 10 people.
Where is Gelteq based?
Gelteq is headquartered in Caulfield, Australia, in the Oceania region.
How does Gelteq make money?
Four revenue lines are on record. Technology Licensing is the primary driver. The others are manufacturing & Distribution Partnership, product Sales (Direct) and contract Development.
Who are Gelteq's main competitors?
Direct peers on record are Catalent, Evonik Industries, Roquette, Ashland, AptarGroup, Gattefossé, Colorcon, SPI Pharma and Lubrizol Life Science. Lonza Group is listed as a broad incumbent.
Does Gelteq have an API?
No public API is recorded for Gelteq.
What industry is Gelteq in?
Gelteq's product category is Drug Delivery Technology. Its primary akta.pro industry code is AFAJACAH, Gelling Agents & Systems (Gelatin, Agar, Gellan, Konjac), with a secondary code of AFAJABAD, Gelatin & Collagen Hydrolysates (Animal-Based Gelling Agents). Its NAICS code is 325412 and its SIC code is 2834.